Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
- PMID: 20376086
- PMCID: PMC2945692
- DOI: 10.1038/leu.2010.56
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
Abstract
Recent whole-genome sequencing efforts led to the identification of IDH1(R132) mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children's Oncology Group trial COG-AAML03P1 (N=257), and Southwest Oncology Group trials SWOG-9031, SWOG-9333 and SWOG-9500 (N=274), were tested for IDH1 mutations. Codon R132 mutations were absent in the pediatric cohort, but were found in 12 of 274 adult patients (4.4%, 95% CI 2.3-7.5). IDH1(R132) mutations occurred most commonly in patients with normal karyotype, and those with FLT3/ITD and NPMc mutations. Patients with IDH1(R132) mutations trended toward higher median diagnostic white blood cell counts (59.2 x 10(9) vs 29.1 x 10(9) per liter, P=0.19) than those without mutations, but the two groups did not differ significantly in age, bone marrow blast percentage, overall survival or relapse-free survival. Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML.
Conflict of interest statement
Conflict of interest disclosure: The authors declare no competing financial interests.
Figures
Similar articles
-
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567020
-
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5. J Hematol Oncol. 2012. PMID: 22397365 Free PMC article.
-
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26. Blood. 2011. PMID: 21873548 Free PMC article.
-
The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients.PLoS One. 2013 Dec 20;8(12):e83334. doi: 10.1371/journal.pone.0083334. eCollection 2013. PLoS One. 2013. PMID: 24376688 Free PMC article.
-
Molecular pathogenesis of AML: translating insights to the clinic.Best Pract Res Clin Haematol. 2013 Sep;26(3):245-8. doi: 10.1016/j.beha.2013.10.003. Epub 2013 Oct 15. Best Pract Res Clin Haematol. 2013. PMID: 24309525 Free PMC article. Review.
Cited by
-
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.Am J Blood Res. 2012;2(4):254-64. Epub 2012 Nov 25. Am J Blood Res. 2012. PMID: 23226625 Free PMC article.
-
Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.J Mol Diagn. 2011 Nov;13(6):678-86. doi: 10.1016/j.jmoldx.2011.06.004. Epub 2011 Sep 1. J Mol Diagn. 2011. PMID: 21889610 Free PMC article.
-
IDH1 and IDH2 mutations in pediatric acute leukemia.Leukemia. 2011 Oct;25(10):1570-7. doi: 10.1038/leu.2011.133. Epub 2011 Jun 7. Leukemia. 2011. PMID: 21647154 Free PMC article.
-
A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors.Clin Transl Med. 2016 Mar;5(1):3. doi: 10.1186/s40169-016-0082-9. Epub 2016 Jan 26. Clin Transl Med. 2016. PMID: 26812134 Free PMC article.
-
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Front Pharmacol. 2017 Dec 7;8:897. doi: 10.3389/fphar.2017.00897. eCollection 2017. Front Pharmacol. 2017. PMID: 29270125 Free PMC article. Review.
References
-
- Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602. - PubMed
-
- Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30:7–11. - PubMed
-
- Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–474. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA027057/CA/NCI NIH HHS/United States
- U10 CA098543-03/CA/NCI NIH HHS/United States
- R21 CA10262-01/CA/NCI NIH HHS/United States
- R01 CA114563-01/CA/NCI NIH HHS/United States
- K23 CA092405/CA/NCI NIH HHS/United States
- N01 CA038926/CA/NCI NIH HHS/United States
- R21 CA102624/CA/NCI NIH HHS/United States
- R01 CA114563-04/CA/NCI NIH HHS/United States
- U10 CA98543/CA/NCI NIH HHS/United States
- CA18029/CA/NCI NIH HHS/United States
- U10 CA032102-30/CA/NCI NIH HHS/United States
- CA12213/CA/NCI NIH HHS/United States
- CA20319/CA/NCI NIH HHS/United States
- K23 CA92405/CA/NCI NIH HHS/United States
- P01 CA018029/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- CA114563/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- N01 CA027057/CA/NCI NIH HHS/United States
- R01 CA114563/CA/NCI NIH HHS/United States
- U10 CA020319/CA/NCI NIH HHS/United States
- U10 CA098543/CA/NCI NIH HHS/United States
- U10 CA038926/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous